Here's Why You Should Invest in SpringWorks (SWTX) Stock Now

SpringWorks Therapeutics' (SWTX) oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023. Following the FDA nod, not only Ogsiveo became the first approved product in the company's portfolio but it also became the first approved drug for treating desmoid tumors, a rare, aggressive tumor of the soft tissues. Ogsiveo has witnessed a strong initial uptake so far. The company's efforts to expand the drug's label ...